Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1963
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1964 1
1974 2
1975 1
1978 1
1980 2
1981 5
1982 1
1983 3
1985 3
1986 2
1987 3
1988 4
1989 10
1990 3
1991 14
1992 6
1993 8
1994 6
1995 8
1996 5
1997 4
1998 7
1999 5
2000 4
2001 3
2002 7
2003 9
2004 9
2005 10
2006 9
2007 11
2008 10
2009 20
2010 13
2011 23
2012 20
2013 32
2014 30
2015 41
2016 29
2017 29
2018 20
2019 30
2020 24
2021 26
2022 22
2023 31
2024 19
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

545 results

Results by year

Filters applied: . Clear all
Page 1
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
Berek JS, Renz M, Kehoe S, Kumar L, Friedlander M. Berek JS, et al. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):61-85. doi: 10.1002/ijgo.13878. Int J Gynaecol Obstet. 2021. PMID: 34669199 Free PMC article. Review.
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high-grade serous carcinomas (HGSC). Stage IC is now divided i …
In 2014, FIGO's Committee for Gynecologic Oncology revised the staging of ovarian cancer, incorporating ovarian, fallopian tube
Global epidemiology of epithelial ovarian cancer.
Webb PM, Jordan SJ. Webb PM, et al. Nat Rev Clin Oncol. 2024 May;21(5):389-400. doi: 10.1038/s41571-024-00881-3. Epub 2024 Mar 28. Nat Rev Clin Oncol. 2024. PMID: 38548868 Review.
Most high-grade serous ovarian carcinomas are now recognized to originate in the fimbrial ends of the fallopian tube. This knowledge has led to more cancers being coded as fallopian tube in origin, which probably explains some of the apparent declines …
Most high-grade serous ovarian carcinomas are now recognized to originate in the fimbrial ends of the fallopian tube. This kno …
Novel Approaches to Ovarian Cancer Screening.
Nebgen DR, Lu KH, Bast RC Jr. Nebgen DR, et al. Curr Oncol Rep. 2019 Jul 26;21(8):75. doi: 10.1007/s11912-019-0816-0. Curr Oncol Rep. 2019. PMID: 31346778 Free PMC article. Review.
Metastasis can occur from ovarian cancers too small to increase blood levels of protein antigens and a significant fraction of ovarian cancers arise from the fimbriae of fallopian tubes that cannot be imaged with TVS. Autoantibodies, miRNA, ctDNA, DNA methylation in blood, …
Metastasis can occur from ovarian cancers too small to increase blood levels of protein antigens and a significant fraction of ovarian cance …
Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT Jr, Drapkin R. Kroeger PT Jr, et al. Curr Opin Obstet Gynecol. 2017 Feb;29(1):26-34. doi: 10.1097/GCO.0000000000000340. Curr Opin Obstet Gynecol. 2017. PMID: 27898521 Free PMC article. Review.
However, recent data suggest that the cells that undergo neoplastic transformation and give rise to the majority of HGSOC are from the fallopian tube. This development has impacted both translational research and clinical practice, revealing new opportunities for ea …
However, recent data suggest that the cells that undergo neoplastic transformation and give rise to the majority of HGSOC are from the fa
Mirvetuximab Soravtansine: First Approval.
Heo YA. Heo YA. Drugs. 2023 Feb;83(3):265-273. doi: 10.1007/s40265-023-01834-3. Drugs. 2023. PMID: 36656533 Review.
In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRalpha positive, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. …
In November 2022, mirvetuximab soravtansine was approved in the USA for the treatment of adult patients with FRalpha positive, platinum-resi …
Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
Weinberger V, Bednarikova M, Cibula D, Zikan M. Weinberger V, et al. Expert Rev Anticancer Ther. 2016 Dec;16(12):1311-1321. doi: 10.1080/14737140.2016.1247699. Epub 2016 Oct 22. Expert Rev Anticancer Ther. 2016. PMID: 27732120 Free article. Review.
Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas, carcinosarcoma and undifferentiated carcinoma with incidence of 0.6% to 7% in BRCA carriers or women with strong family history of …
Serous tubal intraepithelial carcinoma (STIC) is most likely precursor lesion of the most part of high-grade serous pelvis carcinomas …
Revolutionizing the female reproductive system research using microfluidic chip platform.
Yan J, Wu T, Zhang J, Gao Y, Wu JM, Wang S. Yan J, et al. J Nanobiotechnology. 2023 Dec 19;21(1):490. doi: 10.1186/s12951-023-02258-7. J Nanobiotechnology. 2023. PMID: 38111049 Free PMC article. Review.
This review elucidates diverse microfluidic systems in mimicking the ovary, fallopian tube, uterus, placenta and cervix, and we delve into the culture of follicles and oocytes, gametes' manipulation, cryopreservation, and permeability especially. ...
This review elucidates diverse microfluidic systems in mimicking the ovary, fallopian tube, uterus, placenta and cervix, and w …
The Origin of Ovarian Cancer Species and Precancerous Landscape.
Shih IM, Wang Y, Wang TL. Shih IM, et al. Am J Pathol. 2021 Jan;191(1):26-39. doi: 10.1016/j.ajpath.2020.09.006. Epub 2020 Oct 1. Am J Pathol. 2021. PMID: 33011111 Free PMC article. Review.
Unlike other human cancers, in which all primary tumors arise de novo, ovarian epithelial cancers are primarily imported from either endometrial or fallopian tube epithelium. The prevailing paradigm in the genesis of high-grade serous carcinoma (HGSC), the mo …
Unlike other human cancers, in which all primary tumors arise de novo, ovarian epithelial cancers are primarily imported from either endomet …
Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzelmann-Schwarz V. Zwimpfer TA, et al. Cancer Treat Rev. 2023 Jan;112:102497. doi: 10.1016/j.ctrv.2022.102497. Epub 2022 Dec 10. Cancer Treat Rev. 2023. PMID: 36525716 Free article. Review.
High-grade serous ovarian cancers (HGSOCs) most commonly arise from the fimbrial end of the fallopian tube and harbor TP53 gene mutations. In contrast, low-grade serous ovarian cancers (LGSOCs) appear to have different pathological, epidemiological, and clinical fea …
High-grade serous ovarian cancers (HGSOCs) most commonly arise from the fimbrial end of the fallopian tube and harbor TP53 gen …
Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ. Bogani G, et al. Int J Gynecol Cancer. 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. Int J Gynecol Cancer. 2024. PMID: 38101816 Review.
Hence, the US Food and Drug Administration granted accelerated approval of MIRV for patients with FRalpha-positive platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received 1-3 prior systemic treatment regimens. ...
Hence, the US Food and Drug Administration granted accelerated approval of MIRV for patients with FRalpha-positive platinum-resistant epithe …
545 results